Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 44.94 USD 7.9% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one PTGX stock under the Base Case scenario is 18.59 USD. Compared to the current market price of 44.94 USD, Protagonist Therapeutics Inc is Overvalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PTGX Relative Value
Base Case
18.59 USD
Overvaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
56
Median 3Y
10.6
Median 5Y
27.5
Industry
7.7
Forward
9
vs History
1
vs Industry
9
Median 3Y
-6.1
Median 5Y
-7.6
Industry
22.7
Forward
22.5
vs History
1
vs Industry
Median 3Y
-8.6
Median 5Y
-9.8
Industry
21.6
vs History
1
vs Industry
Median 3Y
-8.5
Median 5Y
-9.6
Industry
25.2
vs History
19
vs Industry
24
Median 3Y
3.8
Median 5Y
3.8
Industry
2.5
vs History
60
vs Industry
51
Median 3Y
6.1
Median 5Y
20.1
Industry
7.7
Forward
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9
vs History
1
vs Industry
9
Median 3Y
-3.6
Median 5Y
-4.9
Industry
4.2
Forward
11.3
vs History
1
vs Industry
8
Median 3Y
-3.6
Median 5Y
-4.9
Industry
4.1
Forward
19.2
vs History
1
vs Industry
Median 3Y
-5.4
Median 5Y
-6.6
Industry
5.7
vs History
1
vs Industry
Median 3Y
-5.4
Median 5Y
-6.6
Industry
3.6
vs History
65
vs Industry
29
Median 3Y
35.5
Median 5Y
32.3
Industry
4.6

Multiples Across Competitors

PTGX Competitors Multiples
Protagonist Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
2.7B USD 8.3 15.7 14.7 14.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.7B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
157B USD 4.8 37.1 17.4 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 4 890.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 6 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 175.9
15.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
890.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBITDA: 16.8
14.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.4
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBIT: 21.4
14.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
32.9
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top